2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 381

Muscle Endurance Deficits in Myositis Patients Despite Normal Manual Muscle Testing Scores
Abstract Number: 398

Muscle Function and Health-Related Quality of Life in Patients with Polymyositis and Dermatomyositis
Abstract Number: 399

Musculoskeletal Comorbidities after Total Knee Replacement for Osteoarthritis
Abstract Number: 357

Musculoskeletal Immune-Related Adverse Events with Use of Checkpoint Inhibitors in Malignancy: Experience in Sydney, Australia
Abstract Number: 1652

Musculoskeletal Involvement in Inflammatory Bowel Disease’S Patients: A Mono Centric Experience
Abstract Number: 2260

Musculoskeletal Sarcoidosis: A 15-Year Experience from a Tertiary Care Center in the US
Abstract Number: 1205

Musculoskeletal Ultrasound and Conventional Radiography Evaluation of the Hip in Patients with Calcium Pyrophosphate Deposition Disease
Abstract Number: 1983

Mutations Associated with Clonal Hematopoiesis of Indeterminate Potential Are Found in Peripheral Blood and Synovial Fluid Macrophages from Patients with Rheumatoid and Psoriatic Arthritis
Abstract Number: 1820

Myeloablative Autologous Hematopoietic Stem Cell Transplantation for Severe Scleroderma: Long-Term Outcomes 6-11 Years after Entry on a Randomized Study Comparing Transplantation and Cyclophosphamide
Abstract Number: 1337

Myocardial Fatty Acid Metabolism and Perfusion Mismatch in Scintigraphy Predicts Worse Prognosis in Clinically Amyopathic Dermatomyositis
Abstract Number: 1612

Myocardial Infarctions Among Ankylosing Spondylitis Patients in a Large US Insurance Database
Abstract Number: 2934

Myocardial Microscopic Fibrosis Assessed By T1 Mapping Sequences on Cardiac Magnetic Resonance Imaging Predicts Cardiac Events in Systemic Sclerosis: Data from a Prospective Cohort Study on 40 Patients
Abstract Number: 131

Myofibroblast Cells Expression of CD248 May Contribute to Exacerbate Microvascular Damage during Systemic Sclerosis
Abstract Number: 2286

Myositis and Fasciitis By Magnetic Resonance Imaging in Recent-Onset Polymyalgia Rheumatica and Effect of Tocilizumab Therapy
Abstract Number: 383

Myositis Patients with Anti-U1-RNP and Anti-Ro52 Autoantibodies Are at Risk of Pericarditis, Glomerulonephritis, and Pulmonary Hypertension

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].